Street View: J&J's macro troubles to pass, brokerages say

Johnson & Johnson

14/10/2026 13:29

** Johnson & Johnson JNJ.N on Tuesday missed Wall Street expectations for sales at its medical devices business, hurt by geopolitical issues including the Middle East conflict
** On average, 26 analysts rate stock "buy"; their median PT is $280 - data compiled by LSEG

FOCUS ON 2027
** Raymond James ("outperform," PT: $278) says "the international softness is transient and expect '27 estimates to re-base lower (closer to our estimates), to a healthier, more beatable level"
** J.P. Morgan ("neutral," PT: $285) says macro headwinds including pricing pressure in China and slowdown in Middle East to ease through 2027
** RBC Capital Markets ("outperform," PT: $280) says stock sell-off post results "sets a negative tone for the broader Pharma sector and underscores the heightened volatility in today's market" 
** BofA Global Research ("neutral," PO: $275) sees JNJ as "solid pharma growth stock" but stock's premium valuation and modest consensus upside creates balanced risk-reward 
** Citigroup ("buy," PT: $303) says broader Medtech market remains healthy, but co's challenge is to better convert steady demand into consistent results

 (Reporting by Kanchana Chakravarty in Bengaluru)
 ((Kanchana.Chakravarty@thomsonreuters.com))